Clinical outcomes of hyperprogression based on volumetry in non‐small cell lung cancer after immune checkpoint inhibitor treatment

BACKGROUND: Hyperprogressive disease (HPD) is a novel pattern of the treatment course after immune checkpoint inhibitor (ICI) therapy in patients with non‐small cell lung cancer (NSCLC). This study aimed to investigate the clinical characteristics, outcomes, and associated factors of HPD using a sem...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Jehun, Kim, Taeyun, Jang, Tae Won, Kang, Hee, Kim, Mi Hyun, Yoon, Seong Hoon, Son, Choon‐Hee, Lee, Hyun‐Kyung, Kim, Hyun‐Kuk, Lee, Shin Yup, Shin, Kyeong Choel, Han, Ji‐Yeon, Kang, Eun‐Ju
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9346184/
https://www.ncbi.nlm.nih.gov/pubmed/35785522
http://dx.doi.org/10.1111/1759-7714.14539

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9346184/
https://www.ncbi.nlm.nih.gov/pubmed/35785522
http://dx.doi.org/10.1111/1759-7714.14539

Ejemplares similares